Intercept Pharmaceuticals Targets Commercialization of Breakthrough Therapeutics for Non-Viral Liver Diseases Intercept Pharmaceuticals, Inc., a leading US biopharmaceutical company, is focused on the development and commercialization of therapeutics that target progressive non-viral liver diseases, with a primary focus on the US, Europe and Canada. Its flagship product, Ocaliva, is a farnesoid X receptor agonist that is currently used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept Pharmaceuticals is also developing Ocaliva for indications such as nonalcoholic steatohepatitis and NASH, as well as a number of other product candidates in various stages of clinical and preclinical development. As part of its commercial strategy, the company has signed a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept Pharmaceuticals markets its products through an internal commercial organization and third-party distributors. Founded in 2002 and headquartered in Morristown, New Jersey, Intercept Pharmaceuticals is committed to revolutionizing the treatment of non-viral liver diseases, and is rapidly gaining recognition as a major player in the biopharmaceutical industry. With a strong pipeline of innovative product candidates, the company is well positioned for future growth and success.